India Research

Jun'16 Quarterly PAT

Company	Karvy Est(Rsmn)				
ACC	2,280				
Ambuja	3,243				
UltraTech	7,439				
Shree Cem	2,535				
Ramco Cem	1,411				
JK Cement	568				
JK Lakshmi	389				
Orient Cem	41				
Mangalam Cem	240				
Dalmia Bharat	934				

Source: Karvy Stock Broking

T	-			-	T .
Ratings	and	change	111	Larget	Price

Company	Old	New TP	Ratings
ACC	1,556	1,724	HOLD
Ambuja	230	255	SELL
UltraTech	3,605	3,970	BUY
Shree Cem	12,300	13,550	SELL
Ramco Cem	483	615	HOLD
JK Cement	765	885	BUY
JK Lakshmi	458	525	BUY
Orient Cem	187	216	BUY
Mangalam Cem	255	345	HOLD
Dalmia Bharat	1,130	1,495	BUY

Source: Karvy Stock Broking

Analyst Contact

Vijay Goel

+91-22-6176- 0828 vijay.goel@karvy.com

Cement

Q1FY17E: Strong volumes to drive performance

Aggregate volume growth of coverage is estimated at ~10% YoY in Q1FY17

Industry volume growth for Q1FY16 is expected to be at ~4% YoY, slowing down from significant growth of ~11% YoY seen in Q4FY16. Cement production (as per eight core industries data) grew by 3.4% YoY during Apr-May 2016 as compared to 8% YoY during H2FY16 (which was primarily led by low base). Aggregate volume growth of our cement coverage universe is expected at 9.8% YoY in Q1FY17, indicating market share gain by most of the players. The overall demand had been weak during the year FY16 at 4-5% YoY (vs. ~6% in FY15) because of slow growth in household and corporate capex. The weakness in rural economy (which consists of ~40% of the total country's demand) has been the key drag due to delay in govt spending on infrastructure and slowdown in rural economy. Going ahead, we expect the demand to pick-up during FY17-18E led by increase in Govt. capex towards infrastructure (mainly Roads/Highways and Urban Infra) and pick-up in rural housing sector.

Cement prices in North/Central/West picked up during Apr-June 2016

All India average cement price improved by ~3% on sequential basis led by North, Central and West regions. However, East and South regions have seen some softness during the period. However, the average realisation of our cement coverage universe is expected to be flattish YoY and 3.5% increase on QoQ basis. Ambuja, Shree Cement, JK Cement, JK Lakshmi and Mangalam would be the key beneficiaries.

Aggregate EBITDA of cement universe is expected to increase ~38% YoY

We expect aggregate revenues of our cement universe to increase by ~9% YoY, primarily led by ~10% volume growth as the average realisation has been flattish. Average EBITDA/t is expected to increase by ~26% YoY (led by moderation in costs). Thus, increase in volume coupled with improvement in EBITDA/ton would lead to 38% YoY growth in aggregate EBITDA of our coverage. Coupled with low base effect, companies with recent capacity additions are expected to post better volume growth. Orient, JK Lakshmi and Dalmia are expected to outperform with ~40%/~27%/~23% YoY growth followed by Shree Cement (+20% YoY), Ramco (+16% YoY), JK Cement (+6.8% YoY) and UltraTech (+6% YoY). Other majors like ACC and Ambuja are expected to report muted volume growth of 1.5-2% (due to lack of capacity additions).

Retain positive view on the sector; prefer UTCM, JKLC, JKCE, ORCMNT & DBEL

We maintain our FY17E/18E estimates for the companies under coverage. We maintain positive stance on Cement sector as we believe that improvement in utilisations (led by demand pick-up & slowdown in supply additions) would help in pricing power. We expect significant improvement in EBITDA/t during FY16-18E leading to 29% EBITDA CAGR. We have increased valuation multiples for all the companies considering the improvement in sector dynamics going ahead. We maintain our ratings on all the companies and prefer UltraTech Cement in large-cap cement space and JK Lakshmi, JK Cement, Orient Cement & Dalmia Bharat in mid-caps.



Q1FY17 Estimates

Exhibit 1: June 2016 Result preview

(Rs mn)	June'16E	June'15	YoY (%)	Mar'16	QoQ (%)	Comment						
ACC(ACC IN EQUI	ITY, HOL	D, CMP: I	Rs.1,620, TF	P: Rs1,724,	Mcap: Rs.3	04bn)						
Sales	29,943	29,612	1.1	29,274	2.3	Cement volume is expected to increase by ~2% YoY due to lack of						
EBITDA	3,976	2,795	42.3	3,696	7.6	capacity additions by the company). Net realisation is expected to						
EBITDA margin (%)	13.3	9.4		12.6		increase by ~3% QoQ (flat YoY) because of increase in pricing across North, Central and West regions.						
PBT	3,166	1,771	78.8	3,220	-1.7	Tvorti, central and vvest regions.						
PAT	2,280	1,314	73.5	2,322	-1.8	EBITDA/t is expected to increase by 40% YoY to Rs 631/t led by lower costs which negates the impact of flattish YoY realisation.						
Ambuja Cement(A)	CEM IN E	QUITY, S	ELL, CMP:	Rs.261, TP	P: Rs255, M	(cap: Rs.405bn)						
Sales	25,961	24,928	4.1	24,183	7.4	Cement volume is expected to increase by ~2% YoY due to lack of						
EBITDA	4,936	3,661	34.8	4,235	16.6	capacity additions. Net realisation is expected to increase by ~5% QoQ (+2% YoY) as the prices surged in its selling markets (primarily in						
EBITDA margin (%)	19.0	14.7		17.5		North, Central and West region).						
PBT	4,504	3,094	45.6	4,202	7.2	EBITDA/t is expected to increase by 32% YoY (+23% QoQ) to Rs 823/t.						
PAT	3,243	2,264	43.3	3,038	6.8							
UltraTech Cement(UTCM IN EQUITY, BUY, CMP: Rs.3,487, TP: Rs3970, Mcap: Rs.957bn)												
Sales	64,026	60,382	6.0	64,359	-0.5	Cement volume is expected to increase by ~6% YoY led by ramp-up of						
EBITDA	13,701	10,926	25.4	12,850	6.6	new capacities. Net realisation is expected to increase by ~3% QoQ on						
EBITDA margin (%)	21.4	18.1		20.0		account of increase in cement prices in its selling markets of North, Central and West region.						
PBT	10,191	8,309	22.7	9,301	9.6	EBITDA/t is expected to increase by 18% YoY to Rs 1046/t (+11%						
PAT	7,439	5,908	25.9	6,814	9.2	QoQ).						
Shree Cement(SRC	M IN EQ	UITY, SEL	L, CMP: R	s.16,032, TI	P: Rs13,550,	, Mcap: Rs.559bn)						
Sales	21,214	17,194	23.4	20,174	5.2	Cement volume is expected to increase significantly by ~20% YoY						
EBITDA	6,323	3,516	79.8	5,050	25.2	benefiting from capacity additions in North and East. Cement						
EBITDA margin (%)	29.8	20.4		25.0		realisation is expected to increase by ~9% QoQ on account of surge in prices in North and Central regions.						
PBT	2,983	1,314	127.0	2,182	36.7	EBITDA/t is expected to increase by 52% YoY to Rs 1041/t.						
PAT	2,535	1,281	97.9	2,234	13.5							
Ramco Cement(TRO			LD, CMP:		: Rs615, Mc	cap: Rs.139bn)						
Sales	9,754	9,225	5.7	9,788	-0.4	Cement prices in South region have seen softness during the quarter						
EBITDA	2,906	2,230	30.3	3,093	-6.1	which would lead to 1% QoQ decline in realisation. Cement volume is $$						
EBITDA margin (%)		24.2		31.6		expected to increase by ~16% YoY because of pick-up in demand in South.						
PBT	2,106	1,377	52.9	2,386	-11.7	EBITDA/t is expected to increase by ~13% YoY (down 7% QoQ) to Rs						
PAT	1,411	975	44.7	2,043	-31.0	1384/t on account of moderation in costs.						
JK Cement(JKCE IN						Rs.50bn)						
Sales	9,043	8,107	11.6	9,496	-4.8	Grey cement volume is expected to grow by ~4% YoY led by ramp-up						
EBITDA	1,731	844	105.1	1,730	0.1	of new capacity expansions. White cement (including wall putty)						
EBITDA margin (%)		10.4		18.2		volume is expected to increase by 36% YoY. Grey realisation is						
PBT	811	-11	-7410.0	974	-16.8	expected to increase by ~4% QoQ (due to increase in pricing in North & Central region markets).						
PAT	568	2	35351.6	706	-19.6	Blended EBITDA/t is expected to increase significantly by ~92% YoY						
JK Lakshmi Cemen	t(IKLC IN	LEOUITY	BUY. CM	P: Rs.403	ΓP: Rs525	(+12% QoQ) to Rs 895/t. Mcap: Rs.47bn)						
Sales	7,690	5,908	30.2	7,351	4.6	Cement volume is expected to increase by ~27% YoY benefiting from						
EBITDA	1,257	507	148.0	859	46.4	recent commisioning of cement kiln at Durg (Chhattisgarh). However,						
EBITDA margin (%)		8.6	110.0	11.7	10.1	cement realisation is expected to increase by ~7% QoQ on account of						
PBT	457	-349	NA	305	49.8	increase in prices in North, West and Central regions. EBITDA/t is expected to increase significantly by 95% YoY to Rs 599/t						
						(+50% QoQ).						
PAT	389	-180	NA	484	-19.7							



Orient Cement(ORC	MNT IN	EQUITY,	BUY, CMP	: Rs.182, T	TP: Rs216,	Mcap: Rs.37bn)					
Sales	4,355	3,489	24.8	4,473	-2.6	Cement volume is expected to increase by ~40% YoY led by					
EBITDA	547	591	-7.5	597	-8.3	commissioning of Karnataka Plant. However, softness in cement prices in Telangana and Maharashtra markets during Q1FY17 would lead to					
EBITDA margin (%)	12.6	17.0		13.3		decline in realisation by ~1% QoQ (down by ~11% on YoY). EBITDA/t					
PBT	62	465	-86.7	107	-42.2	is expected to decline significantly by 34% YoY to Rs 402/t led by					
PAT	41	279	-85.3	194	-78.8	sharp YoY decline in realisation.					
Mangalam Cement(MGC IN EQUITY, HOLD, CMP: Rs.305, TP: Rs345, Mcap: Rs.8bn)											
Sales	2,352	2,114	11.3	2,102	11.9	Cement volume is expected to increase by ~6% YoY benefiting from					
EBITDA	464	-41	-1230.9	294	57.6	the commisioning of cement capacity at Morak (Rajasthan). However, cement realisation is expected to increase by ~5% YoY (+9% QoQ) on					
EBITDA margin (%)	19.7	-1.9	(42 bps)	14.0	224 bps	account of increase in prices in North, West and Central regions.					
PBT	293	-207	NA	171	71.3	EBITDA/t is expected to increase significantly by to Rs 717/t (from -Rs					
PAT	240	-188	NA	141	70.2	67/t) led by YoY increase in realisation and decline in costs.					
Dalmia Bharat (DBE)	L IN EQU	JITY, BUY	, CMP: Rs.	1212, TP: 1	Rs1,495, M	Icap: Rs.108bn)					
Sales	18,227	15,720	15.9	18,805	-3.1	Cement volume is expected to increase by ~23% YoY led by full					
EBITDA	4,364	4,012	8.8	5,019	-13.0	consolidation of OCL India and ramp up of recent commissioning of Karnataka Plant. However, softness in cement prices in South & East					
EBITDA margin (%)	23.9	25.5		26.7		during Q1FY17 would lead to decline in realisation by ~1% QoQ					
PBT	1,334	1,461	-8.7	2,710	-50.8	(down by ~6% on YoY). EBITDA/t is expected to decline by 5% YoY to Rs 1109/t led by lower realisation.					
PAT	934	416	124.4	1,149	-18.7	10 110/filed by force remindred.					

Source: Company, Karvy Stock Broking



Re-rating of cement stocks holds a strong case; target prices revised upwards

We maintain positive stance on the Cement sector as we believe that the cement companies are poised for strong earnings growth between FY16-18 led by increase in volumes and realisations with significant improvement in margins during the period. We believe that the cement industry would see a gradual improvement in capacity utilisation rates across the regions (as incremental cement demand is set to outpace incremental cement supply) which would provide pricing power to manufacturers. We estimate all India cement demand to grow at a CAGR of 8% over FY16-18E led by sharp increase in investments in infrastructure and housing segments.

We believe that the companies which have been expanding their capacities or commissioning in the near to medium term stand to benefit from higher volume growth and operating leverage. Many of the companies are operating at high utilization rates, due to their presence in favorable regions and hence, we expect the recent capacity additions to capitalize on the demand revival and boost volumes.

In the large cap space, UltraTech Cement and Shree Cements are expected to see volume growth of ~10% and ~12% (CAGR), respectively, during FY16-18E. ACC and Ambuja Cements are likely to lag behind industry with volume growth of 5-9% (CAGR) during the period. In the mid-cap space, Orient Cement is expected to see strong volume growth of ~22% CAGR over FY16-18E followed by Dalmia (~12%), Ramco (~10%), JK Cement (~9%) and JK Lakshmi Cement (~10%). EBITDA/t is estimated to expand by an average ~Rs320 over the period FY16-18E led by improvement in realisations, cost rationalization and operating leverage benefits.

Outlook on cement stocks

ACC: We have maintained our CY16E/17E estimates. We estimate cement volume to grow at 6% CAGR during CY15-17E and and realisation growth of ~5% during the same period. We expect EBITDA/t to improve to Rs 779/t by CY17E from Rs496/t in CY15, implying EBITDA CAGR of 33% during the period. Valuation at 16.8x/13.1x EV/EBITDA CY16E/17E looks fair (post the recent run up in stock price) even after considering the earnings rebound in CY16-17E and strong balance sheet. We have increased our target multiple to 14x EV/EBITDA for CY17E (earlier 12.5x) to value the stock considering the gradual improvement in sector dynamics (like pick-up in demand, bottoming out of utilisation rates and improvement in pricing) which would lead to strong volume growth, improvement in margins and return ratios going ahead. However, we maintain Hold with a revised target price of Rs 1,724 (earlier Rs 1,556).

Ambuja Cement: We have maintained our CY16E/17E estimates. We estimate cement volume to grow at ~5% CAGR during CY15-17E. We expect EBITDA/t to improve to Rs 1018/t by CY17E from Rs671/t in CY15, implying EBITDA CAGR of 30% during the period. Valuation at 19.8x/14.3x EV/EBITDA CY16E/17E looks expensive (post the recent run-up) considering the low volume growth (losing market share due to lack of capacity expansions) and cash outflow for ACC's stake. Though we have increased target multiple to 14.5x EV/EBITDA to value CY17E standalone EBITDA (from ealier 13x) considering improvement in sector dynamics, we reiterate Sell with a revised target price of Rs 255 (earlier Rs 230).



UltraTech Cement: We have maintained our estimates for FY17E/18E. We estimate cement volume to grow at ~10% CAGR during FY16-18E. We expect EBITDA/t to improve to Rs 1121/t by FY18E from Rs894/t in FY16, implying EBITDA CAGR of 23% during the period. Valuation at 17.6x/13.5x EV/EBITDA FY17E/18E looks attractive (even after the recent run-up in stock price) considering strong volume growth, operating leverage benefits, strong balance sheet (despite continous capex). We have increased target multiple to 15.5x EV/EBITDA to value FY18E EBITDA (from 14x) considering overall improvement in sector dynamics. We maintain Buy with a revised target price of Rs 3,970 (earlier Rs 3,605).

Shree Cement: We have maintained our estimates for FY17E/18E. We estimate strong volume growth of ~12% CAGR during FY16-18E and EBITDA/t improvement to Rs 1241/t by FY18E from Rs709/t in FY16, implying EBITDA CAGR of 49% during the period. Valuation at 23.5x/18x EV/EBITDA FY17E/18E looks expensive (post recent run-up) and has factored in most of the positives. Though we increase target multiple to 15x EV/EBITDA (from 13.5x) for FY18E, we maintain Sell with a revised target price of Rs 13,550 (earlier Rs 12,300).

Dalmia Bharat: We maintain our estimates for FY17E/18E. We estimate strong volume growth of ~12% CAGR during FY16-18E and EBITDA/t improvement to Rs 1341/t by FY18E from Rs1234/t in FY16, implying EBITDA CAGR of 17% during the period. The stock is trading at 8.7x/7.3x EV/EBITDA FY17E/18E which looks attractive considering the strong earnings growth, improvement in margins and simplification of corporate structure. We increase our target multiple to 8.5x EV/EBITDA (from 7x) considering the improvement in sector dynamics (like bottoming out of utilisation rates and improvement in pricing) going ahead. Maintain Buy with a revised target price of Rs 1495 (earlier Rs 1130).

JK Cement: We have maintained our estimates for FY17E/18E. We estimate volume growth of ~9% CAGR during FY16-18E and EBITDA/t improvement to Rs 906/t by FY18E from Rs625/t in FY16, implying EBITDA CAGR of 32% during the period. Valuation at 10.5x/8.0x EV/EBITDA FY17E/18E looks attractive (even after the recent run-up in stock price. We increase target multiple to 9.5x EV/EBITDA (from 8.5x) for FY18E considering improvement in sector fundamentals and maintain Buy with a revised target price of Rs 885 (earlier Rs 765).

JK Lakshmi Cement: We have maintained our estimates for FY17E/18E. However, we estimate strong volume growth of ~10% CAGR during FY16-18E and EBITDA/t improvement to Rs 884/t by FY18E from Rs369/t in FY16, implying EBITDA CAGR of 70% during the period. Valuation at 11.5x/7.5x EV/EBITDA FY17E/18E looks attractive considering better volume growth and realisations going ahead (on account of East India expansion). We have increased target multiple to 9x EV/EBITDA to value FY18E standalone EBITDA (from ealier 8x) considering improvement in sector dynamics. We maintain Buy with a revised target price of Rs 525 (earlier Rs 458).

Ramco Cement: We have maintained our estimates for FY17E/18E. We estimate volume growth of ~10% CAGR during FY16-18E and EBITDA/t improvement to Rs 1,518/t by FY18E from Rs1450/t in FY16, implying EBITDA CAGR of 13% during the period. Valuation at 13.4x/10.9x EV/EBITDA FY17E/18E looks fair (post the recent run-up in stock price) and has factored in most of the positives. We have increased target multiple to 11.5x EV/EBITDA to value FY18E EBITDA (from ealier 9.5x) considering significant improvement expected in south region demand (led by infra activities in AP/Telangana). We maintain Hold with a revised target price of Rs 615 (earlier Rs 483).



Orient Cement: We have maintained our estimates for FY17E/18E. However, we estimate strong volume growth of ~10% CAGR during FY16-18E and EBITDA/t improvement to Rs 872/t by FY18E from Rs399/t in FY16, implying EBITDA CAGR of 80% during the period. The stock is trading at 11.4x/8.3x EV/EBITDA FY17E/18E which looks attractive considering the strong earnings growth after the commissioning of Karnataka plant. We increase our target multiple to 9.5x EV/EBITDA (from 8.5x) considering the improvement in sector dynamics (like bottoming out of utilisation rates in South region and improvement in pricing) going ahead. Maintain Buy with a revised target price of Rs 216 (earlier Rs 187).

Mangalam Cement: We have maintained our estimates for FY17E/18E. We expect volume to grow at ~13% CAGR during FY15-18E and EBITDA/t improvement to Rs 560/t by FY18E from Rs145/t in FY16, implying EBITDA CAGR of 121% during the period. Valuation at 13.8x/6.4x EV/EBITDA FY17E/18E looks fair considering the high sensitivity to decline in realisations. We increase our target multiple to 7x EV/EBITDA (from 6x) considering the improvement in sector dynamics going ahead. We maintain Hold with a revised target price of Rs 345 (earlier Rs 255).

Exhibit 2: Valuation Matrix

Company Name	CMD	Mcap (Rs bn)	TP	Upside/	P/E			EV/EBITDA			EV/Ton (USD)			
	CMP			Downside	Rating	FY16	FY17E	FY18E	FY16	FY17E	FY18E	FY16	FY17E	FY18E
ACC	1620	304	1724	6%	Hold	40.9	30.2	24.0	24.6	16.8	13.1	127	124	119
Ambuja Cement	261	405	255	-2%	Sell	45.5	37.3	25.4	24.2	19.8	14.3	182	180	180
UltraTech Cement	3487	957	3970	14%	Buy	44.0	33.0	24.3	22.1	17.6	13.5	195	191	181
Shree Cement	16032	559	13550	-15%	Sell	122.2	47.5	32.3	41.1	23.5	18.0	320	296	291
Ramco Cement	583	139	615	5%	Hold	24.9	24.8	19.6	14.9	13.4	10.9	159	154	149
Dalmia Bharat	1212	108	1495	23%	Buy	56.4	22.9	17.1	10.7	8.7	7.3	107	105	100
JK Cement	708	50	885	25%	Buy	48.7	20.7	13.3	14.7	10.5	8.0	89	88	83
JK Lakshmi Cement	403	47	525	30%	Buy	279.1	31.2	14.1	23.2	11.5	7.5	114	97	89
Orient Cement	182	37	216	19%	Buy	60.0	27.0	16.7	28.3	11.4	8.3	104	93	90
Mangalam Cement	305	8	345	13%	Hold	-39.7	76.4	10.1	32.9	13.8	6.4	50	44	41

Source: Company, Karvy Stock Broking Note: FY16E/17E/18E denotes CY15E/16E/17E for ACC and Ambuja Cement

Stock Ratings Absolute Returns

Buy > 15% Hold 5-15% Sell < 5%

For further enquiries please contact:

research@karvy.com Tel: +91-22-6149 1500

Disclosures Appendix

Analyst certification

The following analyst(s), who is (are) primarily responsible for this report and whose name(s) is/ are mentioned therein, certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.

Disclaimer

Karvy Stock Broking Limited [KSBL] is a SEBI registered Stock Broker, Depository Participant, Portfolio Manager and also distributes financial products. The subsidiaries and group companies including associates of KSBL provide services as Registrars and Share Transfer Agents, Commodity Broker, Currency and forex broker, merchant banker and underwriter, Investment Advisory services, insurance repository services, financial consultancy and advisory services, realty services, data management, data analytics, market research, solar power, film distribution and production profiling and related services. Therefore associates of KSBL are likely to have business relations with most of the companies whose securities are traded on the exchange platform. The information and views presented in this report are prepared by Karvy Stock Broking Limited and are subject to change without any notice. This report is based on information obtained from public sources, the respective corporate under coverage and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KSBL. While we would endeavor to update the information herein on a reasonable basis, KSBL is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent KSBL from doing so. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KSBL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. This material is for personal information and we are not responsible for any loss incurred based upon it. The investments discussed or recommended in this report may not be suitable for all investors. Investors must make their own investment decisions based on their specific investment objectives and financial position and using such independent advice, as they believe necessary. While acting upon any information or analysis mentioned in this report, investors may please note that neither- KSBL nor any associate companies of KSBL accepts any liability arising from the use of information and views mentioned in this report. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Past performance is not necessarily a guide to future performance. Forward-looking statements are not predictions and may be subject to change without notice. Actual results may differ materially from those set forth in projections

- Associates of KSBL might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.
- Associates of KSBL might have received compensation from the subject company mentioned in the report
 during the period preceding twelve months from the date of this report for investment banking or merchant
 banking or brokerage services from the subject company in the past twelve months or for services rendered
 as Registrar and Share Transfer Agent, Commodity Broker, Currency and forex broker, merchant banker
 and underwriter, Investment Advisory services, insurance repository services, consultancy and advisory
 services, realty services, data processing, profiling and related services or in any other capacity.
- KSBL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.
- Compensation of KSBL's Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.
- KSBL generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
- KSBL or its associates collectively or Research Analysts do not own 1% or more of the equity securities of
 the Company mentioned in the report as of the last day of the month preceding the publication of the
 research report.
- KSBL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report and have no financial interest in the subject company mentioned in this report.
- Accordingly, neither KSBL nor Research Analysts have any material conflict of interest at the time of publication of this report.
- It is confirmed that KSBL and Research Analysts primarily responsible for this report and whose name(s) is/ are mentioned therein of this report have not received any compensation from the subject company mentioned in the report in the preceding twelve months.
- It is confirmed that **Vijay Goel**, Research Analyst did not serve as an officer, director or employee of the companies mentioned in the report.
- KSBL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
- Neither the Research Analysts nor KSBL have been engaged in market making activity for the companies mentioned in the report.
- We submit that no material disciplinary action has been taken on KSBL by any Regulatory Authority impacting Equity Research Analyst activities.

Karvy Stock Broking Limited

Office No. 701, 7th Floor, Hallmark Business Plaza, Opp.-Gurunanak Hospital, Mumbai 400 051 RegdOff: 46, Road No 4, Street No 1, Banjara Hills, Hyderabad – 500 034.

Karvy Stock Broking Research is also available on: Bloomberg - KRVY <GO>, Thomson Publisher & Reuters.